



May Newsletter 2024

ClinTrial Refer Advisors - Welcome Prof Nada Hamad



ClinTrial Refer is a needs driven innovation developed to address a universal problem relating to clinical trials access, referral and recruitment. Since its inception, ClinTrial Refer has adopted a user centered design focus. We continue to seek feedback from patients and clinicians so that the platform remains highly useable and accessible to all stakeholders.

ClinTrial Refer also has access to a generous group of 'Advisors' that contribute feedback and ideas which are helpful to ensuring we are continually evolving in a rapidly changing ecosystem, and that our users needs are met across every touchpoint with the platform.

We would like to extend a very warm welcome and thank you to Prof Nada Hamad who is the newest member to join our esteemed community of Advisors.

Prof Nada Hamad is a senior staff specialist bone marrow transplant, cellular therapies, clinical and

laboratory haematologist at St Vincent's Hospital in Sydney, where she is the director of the haematology clinical trials unit. She is President of Australia and New Zealand Transplant and Cellular Therapies and chairs a number of national and international committees in the field of transplantation and cellular therapies.

Nada is a Professor at the University of New South Wales Sydney (UNSW) and Adjunct Associate Professor at University of Notre Dame Australia, School of Medicine.

Her clinical research interests are in malignant haematology, bone marrow transplantation and cellular therapies. She is passionate about clinical trials access inclusive of diverse populations. Nada is an intersectional feminist with an academic interest in gender equity, diversity and inclusion (EDI) in medicine with an intersectional lens. She is the past deputy co-chair of the UNSW Medicine EDI committee, the past EDI lead for The Lancet Haematology and Women in Global Health Australia National Gender Equality in Health Leadership committee member, amongst a number of other EDI committee leadership positions and memberships.

We are very grateful to have Prof Nada Hamad contribute her wealth of experience and ideas to shaping the continued development of ClinTrial Refer.

Trial Spotlight



Trial Spotlight



On average 28 trials are listed in the ClinTrial Refer database every month

We aim to highlight some of these in our newsletter each month

Search CTR website 

Please find following a list of some studies that are currently open to recruitment in the ClinTrial Refer database.

A Phase 1/2, Open-Label, Dose-Escalation and Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies

The BGB 16673-101 study's key objective is to establish efficacy of this drug in participants who have an unmet need. This study is currently enrolling participants with B-Cell Malignancies, in particular participants with Mantle Cell Lymphoma (MCL).

The key eligibility criteria include a proven diagnosis of MCL; an available tumour block or unstained slides for future pathology central review; MCL disease that is currently relapsed or refractory to last line

of therapy or intolerance to it; measurable disease; no central nervous system involvement; adequate organ functions (heart, liver, kidney); and importantly, prior treatment by both a covalent BTKi (such as zanubrutinib, ibrutinib, acalabrutinib) and an anti-CD20 antibody (such as rituximab).

Slots are also available for participants with CLL (Chronic Lymphocytic Leukemia) or SLL (Small Lymphocytic Leukemia), marginal zone lymphoma, Richter transformation, Waldenström macroglobulinemia, follicular lymphoma, and non-GCB diffuse large B-cell lymphoma.

To learn more about this study and browse the recruiting trial locations, visit the ClinTrial Refer website [here](#).



STUDY TITLE: AN OPEN-LABEL, SINGLE-ARM, MULTI-CENTER PHASE I/IIA CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS EXPRESSING CLAUDIN 18.2

WHAT ARE WE LOOKING FOR? "CLAUDIN 18.2 (PROTEIN) EXPRESSION"
 WE ARE SEEKING INDIVIDUALS DIAGNOSED WITH ADVANCED SOLID TUMORS EXPRESSING CLAUDIN 18.2.(PROTEIN)

PLEASE VISIT THE QR CODE BELOW TO SEE IF YOU'RE ELIGIBLE FOR SCREENING.

WHAT CRITERIA DO THEY NEED TO MEET?

- ✓ DIAGNOSIS OF ADVANCED SOLID TUMORS (GASTRIC (GEJ) OR PANCREATIC) EXPRESSING CLAUDIN 18.2
- ✓ AGE >18
- ✓ WILLINGNESS TO PROVIDE INFORMED CONSENT
- ✓ OTHER ELIGIBILITY CRITERIA MAY APPLY. CONTACT US FOR MORE DETAILS.

WHY PARTICIPATE?

- ✓ ACCESS TO INNOVATIVE TREATMENT/S
- ✓ COMPREHENSIVE MEDICAL EVALUATIONS
- ✓ CLOSE MONITORING BY EXPERIENCED HEALTHCARE PROFESSIONALS
- ✓ POSSIBLE BENEFITS FROM POTENTIAL NEW TREATMENT OPTION.

MAKE A DIFFERENCE: YOUR PARTICIPATION CAN PAVE THE WAY FOR BETTER TREATMENTS FOR ADVANCED SOLID TUMORS.

WHY ARE WE DOING THE TRIAL?

OUR STUDY AIMS TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS EXPRESSING CLAUDIN 18.2 (PROTEIN). BY PARTICIPATING IN THIS TRIAL, YOU CAN CONTRIBUTE TO THE ADVANCEMENT OF MEDICAL KNOWLEDGE AND POTENTIALLY BENEFIT FROM INNOVATIVE TREATMENT OPTIONS.

DURATION OF THE STUDY: YOU WILL PARTICIPATE IN THIS STUDY UNTIL IT IS NO LONGER BENEFITTING YOU OR YOU DECIDE TO WITHDRAW FROM THE STUDY.

LEARN MORE : TO LEARN MORE ABOUT OUR CLINICAL STUDY AND SEE IF THE STUDY IS RIGHT FOR YOU TO PARTICIPATE, VISIT OUR STUDY PAGE ON THE CLINICAL STUDY REGISTRY PLATFORM CLINICALTRIAL. GOV IDENTIFIER: NCT05277168

STUDY DETAILS | A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS | CLINICALTRIALS.GOV

ACTIVELY RECRUITING ACROSS AUSTRALIA !!!! LOCATIONS !!!

NEW SOUTH WALES (NSW)
 LIVERPOOL, SYDNEY SOUTH WEST PRIVATE HOSPITAL
 AFLAH ROOHULLAH,
 CONTACT NO. 02 8738 5180

SCIENTIA CLINICAL RESEARCH LTD
 CHARLOTTE LEMECH,
 CONTACT NO. 02 9382 5800

MACQUARIE UNIVERSITY HOSPITAL
 ANDREW PARSONSON,
 CONTACT NO. 02 9812 3614

WESTMEAD PUBLIC HOSPITAL
 ADNAN NAGRAL,
 CONTACT NO. 02 8890 8383


VICTORIA (VIC)
 PENINSULA AND SOUTH EASTERN HAEMATOLOGY & ONCOLOGY GROUP (PASO),
 FRANKSTON VIC 3199.
 VINOD GANJU,
 CONTACT NO. 03 9781 5244

WESTERN AUSTRALIA (WA)
 ONE CLINICAL RESEARCH (OCR), NEDLANDS, WA 8000
 ADNAN KHATTAK,
 CONTACT NO. 0452 146 726



SCAN ME

You can also click on the link to access this trial [here](#).



**SYDNEY PAIN
MANAGEMENT CENTRE**

**PARTICIPANTS FOR A CLINICAL STUDY OF
CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY (CIPN)
TODAY**


**NOW RECRUITING PARTICIPANTS FOR A
CLINICAL TRIAL OF A POTENTIAL NEW
THERAPY FOR PAIN MANAGEMENT IN
CIPN PATIENTS IN AUSTRALIA**

Payment for your time and travel

Click [here](#) to access trial details on the ClinTrial Refer website.

Change Notification Preferences

Did you know you can change your notification preferences in the App? Simple follow the instructions below to control how you receive notifications.



To change your notification preferences, go to the Settings menu and switch them on or off. A blue switch means ON and grey means OFF.

Do you have something to share?

Share your story if you have taken part in a clinical trial or supported someone through a trial. Your stories and thoughts are important to us and can be a great encouragement to others. If you'd like to share a clinical trial story please email us at admin@clintrialreferapp.com. We'd love to hear from you.





ADDRESS

ClinTrial Refer c/o Ground Floor,
W R Pitney Building, St George Hospital,
Gray Street, KOGARAH 2217
Australia

EMAIL

www.clintrialrefer.org.au/

admin@clintrialreferapp.com

[Unsubscribe](#)

Copyright © *2019* *ClinTrial Refer*, All rights reserved.

This email was sent to <<Email Address>>
[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)
ClinTrialRefer · St George Hospital · Gray Street · Kogarah, Nsw 2017 · Australia